Compounded tirzepatide for PCOS: what the evidence actually supports

What did @hopiedopiee1 actually say?

Straightforwardly: nothing about GLP-1s, PCOS, tirzepatide, or any health topic. The transcript is song lyrics, possibly from a Drake or Toronto rap track, with lines about clubs, relationships, and street geography. There is no spoken medical content here. The hashtags (#glp1, #pcos, #compoundedtirzepatide, #amble) are doing a lot of work that the video itself is not doing.

This is a pattern worth noting. Creators sometimes tag health-adjacent hashtags to reach an audience already interested in GLP-1 medications without actually making any verifiable claims. Whether this is intentional or incidental, the result is the same: a viewer searching for information about compounded tirzepatide or PCOS treatment lands on a video that tells them nothing useful and nothing harmful.

Does the science back this up?

There is no claim in the transcript to evaluate against the science. But since 30,400 people found this video through GLP-1 and PCOS hashtags, it is worth covering what the actual evidence says about those topics.

Tirzepatide, the active ingredient in Mounjaro and Zepbound, is a dual GIP and GLP-1 receptor agonist. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed a mean weight reduction of up to 22.5% in adults with obesity over 72 weeks. For PCOS specifically, weight loss through GLP-1 receptor agonists has shown improvements in menstrual regularity, androgen levels, and insulin sensitivity, though tirzepatide-specific PCOS trials are still limited. A 2023 review by Jensterle et al. in the International Journal of Molecular Sciences noted that GLP-1 receptor agonists address several pathophysiological drivers of PCOS simultaneously.

What did they get wrong (or right)?

They got nothing wrong medically, because they said nothing medical. The lyrics contain no health misinformation. That is the only genuinely accurate thing to report here.

What is worth flagging is the hashtag strategy itself. Tagging #compoundedtirzepatide in a video that has no content about compounded tirzepatide contributes to an information environment where that hashtag becomes associated with low-signal content. For patients researching compounded GLP-1 options, this kind of video crowds out substantive information without adding anything in return.

It is also worth being direct about compounded tirzepatide specifically. Compounded versions of tirzepatide are not FDA-approved and are not equivalent to Zepbound or Mounjaro. The FDA has warned that compounded tirzepatide products vary in formulation, concentration, and purity. Any platform or creator claiming otherwise would be spreading misinformation. This video does not make that mistake, but the hashtag alone can create an implied association.

What should you actually know?

If you arrived here because you are researching tirzepatide for PCOS or weight management, here is what the evidence actually supports.

• Tirzepatide is approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). It is not FDA-approved specifically for PCOS.
• Compounded tirzepatide is a different product from brand-name tirzepatide. The FDA placed compounded semaglutide and tirzepatide under increased scrutiny in 2024 following reports of dosing errors and adverse events from compounded formulations.
• PCOS affects roughly 8-13% of reproductive-age women globally, according to the World Health Organization, and insulin resistance is a common feature. GLP-1 receptor agonists address insulin resistance directly, which is why researchers are actively studying them for PCOS management.
• No GLP-1 medication cures PCOS. Weight loss and hormonal improvements are documented, but they are management outcomes, not curative ones.
• If a TikTok video is tagged with medication hashtags but contains no actual information, that is a signal to find a more reliable source before making any treatment decisions.